trending Market Intelligence /marketintelligence/en/news-insights/trending/gdrezi1_9fgszxivvcjbzg2 content esgSubNav
In This List

Teva's $235M payment verdict for infringing GSK patent gets overturned

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Teva's $235M payment verdict for infringing GSK patent gets overturned

A U.S. District Judge reversed a previous decision that awarded GlaxoSmithKline PLC a payment of about $235 million from Teva Pharmaceutical Industries Ltd. for infringing a GSK patent for its blood pressure medicine Coreg, Reuters reported March 28.

GSK had claimed that Teva added treatment of chronic heart failure to the label of its generic version of Coreg in 2011 when that usage was under patent protection. It also claimed that Teva caused doctors to infringe the patent when it sold the generic version and marketed it as a substitute for Coreg.

Judge Leonard Stark stated that there was no evidence to support the finding that Teva's sales of the generic version caused doctors to infringe the patent, according to the news outlet.

The previous ruling had awarded the British drugmaker $234.1 million in lost profits, $1.4 million in royalties and rejected the Israeli generic drugmaker's assertion that the patent was invalid. Stark did not reverse the previous decision regarding the validity of the patent.

In a statement, GSK expressed its disappointment with the decision and stated that it is reviewing its options, while Teva declined to comment, Reuters reported.

The U.S. Food and Drug Administration had approved Teva's generic version of Coreg, or carvedilol, in 2007.